Study of Ocrelizumab Given by Subcutaneous Injection for Adults With Multiple Sclerosis Switching From Other Anti-CD20 Treatments

What this Trial Is About

Researchers are evaluating the use of ocrelizumab OCR combined with recombinant human hyaluronidase rHuPH20 delivered under the skin for people with relapsing multiple sclerosis RMS or primary progressive multiple sclerosis PPMS. This study focuses on participants who have switched from other approved anti-CD20 therapies for RMS or PPMS. The goal is to assess imaging markers, patient outcomes, safety, tolerability, and how satisfied patients are with the treatment. Participants will receive two doses of ocrelizumab administered subcutaneously one at the start of the study Day 1 and another at Week 24. This single group study monitors these doses while participants have switched from previous anti-CD20 therapies such as ofatumumab, ublituximab-xiiy, or intravenous ocrelizumab. The study is conducted over a period leading up to Week 48 to capture treatment effects and satisfaction. During the study, participants will undergo brain MRI scans at baseline, Week 24, and Week 48 to monitor lesions. Researchers will also track adverse events, changes in B-cell counts, and patient-reported outcomes including treatment satisfaction and impact on daily life. Assessments include questionnaires for treatment satisfaction and multiple sclerosis impact, with safety monitored throughout. The total study duration extends to February 2029, with regular evaluations to measure the treatments effect and safety.

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy